What is NDC 0009-4709?

0009-4709 is the product NDC for Depo-SubQ Provera (medroxyprogesterone acetate), Medroxyprogesterone acetate 104 mg/.65mL injection, suspension, listed with the FDA by Pharmacia & Upjohn Company LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Depo-SubQ Provera (Medroxyprogesterone acetate).

Pharmacia & Upjohn Company LLC, NDC labeler code 0009. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Depo-SubQ Provera?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Depo-SubQ Provera NDC 0009-4709 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)0009-4709Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00009-4709Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0009-4709-13	00009470913	1 SYRINGE in 1 CARTON (0009-4709-13) / .65 mL in 1 SYRINGEMarketed from May 2, 2005

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Depo-SubQ Provera
Generic name (nonproprietary): medroxyprogesterone acetate
Active ingredients: Medroxyprogesterone acetate — 104 mg/.65mL
Dosage form: Injection, Suspension
Route: Subcutaneous
Labeler: Pharmacia & Upjohn Company LLCNDC labeler code 0009
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021583
Marketing start: May 2, 2005
Listing expires: Dec 31, 2026
Other FDA classes: Progesterone Congeners (Chemical structure)
Identifiers: Product ID 0009-4709_641b0fea-8376-4405-aea2-ac972c4a65ebSPL ID 641b0fea-8376-4405-aea2-ac972c4a65ebSPL set ID 390087a6-f3c3-4f0b-a930-79acf412f153RxCUI 1000156, 1000158UNII C2QI4IOI2G
Pharmacologic class: Progestin

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400009470913 followed by a unit qualifier and the quantity

Package 00009-4709-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 18, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Depo-subQ provera 104 is indicated in females of reproductive age for: • Prevention of pregnancy and • Management of endometriosis-associated pain. Depo-subQ provera 104 is a progestin that is indicated in females of reproductive age for: • Prevention of pregnancy. ( 1 ) • Management of endometriosis-associated pain. ( 1 ) Limitations of Use : Use of depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate. ( 1 , 5.1 ) Limitations of Use : The use of depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0009-4709

What is NDC 0009-4709?: 0009-4709 is the product NDC for Depo-SubQ Provera (medroxyprogesterone acetate), Medroxyprogesterone acetate 104 mg/.65mL injection, suspension, listed with the FDA by Pharmacia & Upjohn Company LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Depo-SubQ Provera (Medroxyprogesterone acetate).
What is the active ingredient?: Medroxyprogesterone acetate.
Who is the labeler?: Pharmacia & Upjohn Company LLC, NDC labeler code 0009. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Depo-SubQ Provera?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Depo-SubQ Provera (Medroxyprogesterone acetate) NDC 0009-4709